StockWatch
·

SHILPA MEDICARE LTD. Q2 FY27 Results

SHILPAMEDQ2 FY27 Results
Filing
Result:Good· Market: Flat#Margin squeeze

Outlook: Cautiously Optimistic · Guidance: None

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue529.1213.6%43.0%
Total Income537.7714.7%44.7%
Expenditure433.6915.1%41.2%
PBT103.5312.4%60.4%
Net Profit79.1921.5%79.7%
OPM26.81%2.44pp2.46pp
NPM14.73%6.78pp2.88pp
EPS4.0521.5%80.0%
View full financials

Revenue growth of 43% YoY hit a 6-quarter high, but OPM compressed to 26.8% from 29.3% as API/CDMO ramp-up costs scaled, and the 79.7% PAT jump leaned more on a lower effective tax rate (23.5% vs 31.6%) than on operating leverage, keeping this healthy-but-not-standout.

SHILPA MEDICARE LTD. · QQ2 FY-2027 · THE CALL

Record revenue, margin pressure emerging; CDMO momentum solid but execution uncertain

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

11 Nov 2026 · 6 min read
Verdict

Hold

confidence 7/10

Credibility

Grade B

Hit H1 revenue/growth targets (44% YoY). PAT strong YoY but QoQ decline (−21.5%) unexplained. Rotigotine delayed 6 months.

Short-term outlook

Cautiously Optimistic

next 1–2 quarters

Long-term outlook

Optimistic

multi-year

Strong CDMO momentum (150% growth, 25+ NCE programs) and Biologics upside are structural tailwinds. But near-term headwinds from gross margin compression (−700 bps), QoQ profit decline (−21.5%) despite revenue growth (+13.6%), and Rotigotine delay signal execution friction. Management bullish but cautious on forward visibility.

₹538 Cr

Revenue · +43% YoY

₹79 Cr

Reported PAT · +79.7% YoY

Compressing

Margins · vs guidance: Mixed

Did the claims hold up?

Management's claims vs. the numbers

Highest ever quarterly revenue

OVERSTATED

₹529.1 Cr delivered; CFO claimed ₹538 Cr (+43% YoY actual vs 35% stated)

All 4 engines firing with strong growth

MET

API +24%, Formulation +50%, CDMO +150%, Biologics +150% YoY

Highest ever EBITDA ₹151 Cr, 28% margin

MET

₹151 Cr confirmed; margin 28.5% aligns

Gross margins down 700 bps QoQ/YoY

MET

OPM 26.8%, down from API cost inflation acknowledged

PAT ₹79 Cr for quarter

MET

₹79.2 Cr delivered; exact match

Earnings quality

What changed since the last call

Deltas vs. the prior call

Rotigotine launch timing

Downgrade

Delayed from FY27 to FY28 H1 (~6 months slip) due to European agency variation approval for raw material.

Biologics strategic elevation

Upgrade

Now 12% of revenue (₹65 Cr, +150% YoY), reframed from 'asset under monetization' to 'real business focus'. 7 biosimilars, 2 entering Phase I FY27.

CDMO commercialization pace

Upgrade

25+ NCE programs with partners; 4 expected to commercialize in 18–24 months. Japanese programs showing traction.

Margin pressure acknowledged

Neutral

API raw material cost surge compressed gross margins 700 bps. Management expects recovery when commodity prices normalize; timeline vague.

Capex intensity continues

Neutral

₹252 Cr spent H1 on peptide capacity expansion. Expected ~₹500 Cr FY27 (vs ₹456 Cr prior ₹114Cr/quarter guidance). ROCE uplift timing uncertain.

The Q&A

Analysts pressed hard on margin recovery timeline (Parth Mehta), forward guidance (Aryan Mehta), capacity utilization (Gaurav Shukla), segment profitability (Loveleen Bagga). Management held firm on 'no numeric guidance' policy. Answered product/operational questions directly but protected forward visibility. Overall: selective but not evasive.

The exchanges that mattered

Gross margin compression — Parth Mehta, Vallum Capital

Partial

API strong but lower-margin vs formulation. Raw material costs rose; not fully passed to customers. Temporary, expects recovery.

Peptides capex — Manish Bhandari

Answered

4 manufacturing lines currently, adding 2 more. Building one of India's largest peptide capacities by end FY27. Space for further expansion.

Peptides utilization — Gaurav Shukla

Dodged

Depends on customer uptake. Will give visibility H2 FY27 when confident. Capacities planned based on customer indications.

CDMO order book — Shrikant Akolkar, Nuvama

Partial

No orders in hand yet. Indication from customers based on planned capacity. Will share visibility next year.

Ondansetron launch — Krisha Kansara, The Boring AMC

Answered

FDA approval pending. Launch expected FY28 H1 after central approval. Marketing partner already tied up.

Specialty CDMO growth FY28 — Aryan Mehta, Shrayas Capital

Dodged

Cannot give forward guidance. Good growth possible based on program complexity. Partner uptake determines outcome.

New molecule launches — Athul Joby, Prosperity Wealth

Partial

Details in investor presentation segment-wise. Cannot compare Nor-UDCA. Refer to presentation, reach out separately.

Jadcherla plant risk — Amish Kanani

Answered

No current revenue risk. Moved critical filings to alternate CMO sites. EU plant cleared again. U.S. business independent of Jadcherla.

Rotigotine delay — Sumit Gupta, Antique

Answered

Delayed couple quarters for European agency variation approval of raw material. Set to launch FY28 H1.

Service/licensing income — Loveleen Bagga, Systematix

Partial

Service income has R&D development costs attached. Not 100% margin. Cannot disclose segment proportion.

Guidance

Forward guidance and management's confidence

Capex ~₹114 Cr/quarter through FY27 as previously guided

High

₹252 Cr H1 spent on peptide/CDMO capacity. On track to commission largest peptide capacity by FY27 end.

Risks the call surfaced

Ranked by how much they should concern a holder

Gross margin recovery

Medium

Gross margins down 700 bps due to API raw material inflation. Management expects recovery when commodity prices normalize, but no timeline or confidence level given.

QoQ profit decline

Medium

Q2 PAT ₹79.2 Cr down 21.5% from implied Q1 ₹100.8 Cr, despite QoQ revenue growth of 13.6%. Not explained on call. Suggests seasonal pattern, one-time Q1 items, or cost control deterioration.

CDMO commercialization

Medium

CDMO revenue +150% YoY with 25+ NCE programs in pipeline. 4 expected commercialization in 18–24 months, but detail on ramp/timing lacking. Success depends on partner execution, not solely Shilpa capability.

Product launch delays

Low

Rotigotine delayed FY27 to FY28 H1 (~6 months) for European agency variation approval. Ondansetron also delayed to FY28 H1. Reduces near-term growth catalysts.

Capex payoff timing

Low

Heavy capex cycle (~₹250 Cr per half) to build peptide/CDMO capacity. ROCE at 18.3% adjusted, but normalized return level uncertain. Utilization depends on CDMO customer demand.

Management

Score 7/10. Clear on product roadmap and operational metrics. Deliberately avoids numeric forward guidance ('no formal guidance' policy). Explains margin pressure and cost drivers directly. Transparent on Rotigotine delay. Hit H1 revenue target (44% YoY growth). PAT growth 80% YoY. But QoQ profit decline unexplained; margin compression acknowledged with vague recovery timeline. Rotigotine delayed 6 months. Solid execution with emerging cracks.

What to watch next
  • 1 · FY28 H1

    Rotigotine launch in Europe/RoW after regulatory delay

  • 2 · FY28 H1

    Ondansetron FDA launch in India markets expected

  • 3 · FY27 Q3–Q4

    First CDMO program commercialization (Nivolumab/Aflibercept expected)

Management bullish but cautious on forward visibility.

Informational and educational content only. Not investment advice.